Hairong Lyu

No. 24 Fu Kang Road
Changhongjie, 300192, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Prognostic factor analysis of CD19 CAR-T therapy followed by hematopoietic stem cell transplantation in relapsed/refractory B-ALL.

Prognostic factor analysis of CD19 CAR-T therapy followed by hematopoietic stem cell transplantation in relapsed/refractory B-ALL.

Journal: Clinical and experimental medicine

Published: April 15, 2026

Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax.

Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax.

Journal: Annals of hematology

Published: March 30, 2026

Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Defining a Therapeutic Window for Venetoclax in Post-Transplant Maintenance Therapy for High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Journal: Hematological oncology

Published: February 17, 2026

Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies.

Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies.

Journal: Frontiers in immunology

Published: September 30, 2025

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

Journal: Journal of hematology & oncology

Published: September 02, 2025

Metagenomics next-generation sequencing of plasma combined with blood cells for improving the prognosis of early infection in patients with hematologic disorders: a real-world cohort study in northern China.

Metagenomics next-generation sequencing of plasma combined with blood cells for improving the prognosis of early infection in patients with hematologic disorders: a real-world cohort study in northern China.

Journal: Frontiers in molecular biosciences

Published: July 29, 2025

Correction: Infectious complications distribution following CLL1 CAR-T cell therapy for acute myeloid leukemia.

Correction: Infectious complications distribution following CLL1 CAR-T cell therapy for acute myeloid leukemia.

Journal: Cancer immunology, immunotherapy : CII

Published: June 04, 2025

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.

Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.

Journal: Frontiers in immunology

Published: November 19, 2024

Unlocking the healthy human microbiome: Redefining core microbial signatures.

Unlocking the healthy human microbiome: Redefining core microbial signatures.

Journal: Acta pharmaceutica Sinica. B

Published: November 19, 2024

Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report.

Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report.

Journal: Blood advances

Published: October 03, 2024

Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.

Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.

Journal: Frontiers in immunology

Published: September 04, 2024

Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia.

Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia.

Journal: Chinese medical journal

Published: May 07, 2024

Showing 1-12 of 26

Last Updated: 09/26/2026